Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Elinzanetant Formulations in Healthy Volunteers
NCT05351892Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elinzanetant in vasomotor symptoms (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration versus time curve from zero to infinity and Maximum observed drug concentration. Started May 2022; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05351892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351892.